Latest News
-
Landscape study on patent filing – CAR T-cell Immunotherapy
This study commissioned by the European Patent Office demonstrates the application of patent information to gain insights into specific technological fields, in this case Chimeric Antigen Receptor T-cell Immunotherapy (CAR T-cell Immunotherapy). If you are interested in finding out more about patents in the field of CAR T-cell immunotherapy, a... -
CARAT Fellowship Programme 2019: Seven exceptional scientists benefit from unique know-how
To enable more and more experts to use innovative cell manufacturing technology: this is the goal of the CARAT Training Fellowship Programme. In December 2019, seven talented scientists participated in the TCT training course at the MACS Academy in Bergisch Gladbach. -
ATMP-Workshop: CAR T cell therapies in Europe
Despite the potential of CAR T cell therapies, there are still significant hurdles in Europe to be overcome during their development, approval process, and reimbursement. On December 3 over hundred experts met at the invitation of BIO.NRW and Miltenyi Biotec at ATMP Workshop in Brussels to come up with solutions and make these novel therapies... -
Joint CARAT/RESTORE survey to identify obstacles in translation of CAR T and ATMP into clinical application
CARAT together with the EU initiative RESTORE are conducting a joint survey within our research networks to identify the most important technological, regulatory, clinical and ethical hurdles for translation of CAR T and ATMP into clinical application. The short anonymous survey includes just 12 questions and will take roughly 7 minutes to... -
Taking the Final Leap: CARAT Meeting in Bergisch Gladbach
It seems like yesterday that the CARAT partners met for the first time at their kick-off meeting in Bergisch Gladbach, Germany, in 2016. Now, almost four years later on 4-5 November 2019, the consortium returned to the same place to conclude the project. The meeting was hosted by the coordinator Miltenyi in the impressive Kardinal Schulte Haus... -
CAR T cell therapy in solid tumours
While CAR T cell therapy has been very successful in the past years with regard to hematologic malignancies, the translation to solid tumours remains a challenge. Now, the results of two trials in the US with mesothelin and claudin 18.2 targeted CAR T cells are very promising and indicate that the therapy can be successfully applied also to... -
CARAT Continues Its Journey in the Field of CAR T Cell Therapy
Having entered the final project year, the CARAT consortium gathered on 7-8 March, 2019 in Langen, Germany, for their 4th Progress Meeting. The meeting was hosted by Paul-Ehrlich-Institut, a German federal authority in the field of medicinal products and partner in CARAT. While the project progress was assessed extensively by the partners during... -
CARAT Training Fellowship
GMP-compliant CAR T Cell Manufacturing Training Course December 9-13, 2019